LPA Variant (rs10455872)

This is one of the few cardiovascular tests where your result has been the same since the day you were born and will not change for the rest of your life. The single letter difference this test looks for in your LPA gene quietly drives up a hidden cholesterol-like particle called lipoprotein(a), abbreviated Lp(a), every day from childhood onward.

That matters because Lp(a) is one of the strongest inherited risk factors for early heart disease and aortic valve disease, and a standard cholesterol panel is essentially blind to it. Knowing whether you carry this variant tells you something a lifetime of LDL tests cannot: whether your genes have been quietly stacking the deck against your heart and valves.

What This Variant Actually Does

rs10455872 is a single-letter change in the LPA gene, the gene that builds the protein backbone of Lp(a) (lipoprotein little a). Carriers tend to make smaller versions of that protein, which the liver releases into the bloodstream much more efficiently than the larger versions non-carriers produce.

Lp(a) itself is an LDL-like particle made almost entirely in liver cells. About 70 to 90 percent of how much Lp(a) you have circulating is decided by genetics, and rs10455872 is one of the strongest single signals known. Once your liver is set up to pump out high levels, no amount of diet, exercise, or standard statin therapy can meaningfully change the underlying tendency.

Heart Attack and Coronary Artery Disease

This is the headline risk. In a study of about 16,000 adults, each copy of the rs10455872 risk allele was associated with roughly 70 percent higher odds of coronary disease, and the link was driven almost entirely by the variant's effect on Lp(a) levels.

In a study of 1,394 Brazilian patients undergoing coronary angiography (a procedure that uses dye and X-rays to look directly at heart arteries), carriers of the variant had about double the odds of having significant blockages, and their lesion scores were higher overall. The pattern shows up across populations: more carriers, more atherosclerotic disease, often appearing earlier in life than traditional risk factors would predict.

Aortic Valve Stenosis

The second major risk associated with this variant is calcific aortic valve disease, where calcium deposits gradually stiffen the valve that controls blood flow out of the heart. In a study of 44,703 adults using diagnostic and procedural records, people carrying two copies of LPA risk variants had roughly twice the odds of developing aortic stenosis compared with non-carriers.

In the Copenhagen General Population Study of 77,680 Danish adults, genetically higher Lp(a) driven by this variant translated to about 60 percent higher risk of aortic valve stenosis for every tenfold rise in Lp(a). A meta-analysis of multiple studies confirms the connection: carriers tend to develop micro-calcification earlier and progress to clinical valve disease faster.

When It Hides Inside a Familial Hypercholesterolemia Diagnosis

Familial hypercholesterolemia, or FH, is the inherited condition that causes lifelong high LDL cholesterol. In a registry of 1,695 people clinically diagnosed with FH, about 4.6 percent of cases turned out to be largely explained by an LPA variant rather than a classic FH mutation. The Lp(a) was inflating their LDL reading and mimicking FH on paper.

In a separate study of 668 genetically confirmed FH patients, carriers of rs10455872 had roughly twice the odds of premature cardiovascular disease and tended to have their first event about 4 years earlier than non-carriers. If you carry both an FH mutation and this variant, your risk is layered, not just additive.

How Results Are Reported

Unlike most blood tests, this is a yes-or-no genetic readout with three possible answers. The risk allele frequency varies by ancestry, which is why labs do not assign 'optimal' or 'borderline' tiers the way they would for cholesterol. The categories below come from the underlying genetic studies and are most thoroughly validated in European-ancestry populations.

What this means for you: a positive result does not diagnose disease. It tells you that one of the strongest inherited drivers of high Lp(a) is present in your DNA, which makes measuring your actual Lp(a) protein level the essential next step.

Why You Only Need This Test Once

Your DNA does not change. A genotype test for rs10455872 done at age 25 will give the same result at age 65. Repeat genetic testing has no value, and labs that report it as such are wasting your money.

Where ongoing testing matters is the downstream marker this variant influences. Lp(a) protein concentrations have meaningful variability over time, with about 20 to 40 percent of people showing changes greater than 25 percent between two measurements. Get a baseline Lp(a) blood test once you know your genotype, repeat it within 3 to 6 months if the first reading sits in an intermediate range, and at least annually thereafter to track whether emerging Lp(a)-lowering therapies are working if you start one.

What to Do If You Carry the Variant

Carrying rs10455872 is not a diagnosis, but it should change your prevention strategy. The most useful next steps fall into three categories:

• Measure your actual Lp(a): the genetic test predicts a tendency, but a direct Lp(a) blood test (reported in nmol/L or mg/dL) tells you the level you are actually living with.
• Get the rest of your atherogenic lipid picture: ApoB (apolipoprotein B, a count of every artery-clogging particle) and a direct LDL-C measurement help quantify how much additional cholesterol-driven risk you carry on top of the inherited Lp(a) burden.
• Consider specialist input if your numbers are extreme or if you have premature heart disease: a lipidologist or preventive cardiologist can help you decide whether aggressive LDL lowering, lifestyle intensification, or enrollment in trials of Lp(a)-targeted therapies makes sense for you.

Carrying the variant does not mean you are destined for a heart attack. In a study of 14,051 adults, people with high Lp(a) levels or genotypes who maintained ideal cardiovascular health, including a healthy weight, good diet, regular activity, no smoking, and well-controlled blood pressure and cholesterol, had substantially lower event rates than carriers with poor risk profiles. The genetic hand you were dealt sets the stakes higher; how you play the rest of your risk factors still decides much of the outcome.